Masitinib is safe and effective for the treatment of canine mast cell tumors.

@article{Hahn2008MasitinibIS,
  title={Masitinib is safe and effective for the treatment of canine mast cell tumors.},
  author={K. Hahn and G. Ogilvie and T. Rusk and P. Devauchelle and A. LeBlanc and A. Legendre and B. Powers and P. S. Leventhal and J. Kinet and F. Palm{\'e}rini and P. Dubreuil and A. Moussy and O. Hermine},
  journal={Journal of veterinary internal medicine},
  year={2008},
  volume={22 6},
  pages={
          1301-9
        }
}
BACKGROUND Activation of the KIT receptor tyrosine kinase is associated with the development of canine mast cell tumors (MCT). HYPOTHESIS/OBJECTIVE To evaluate the efficacy of masitinib, a potent and selective inhibitor of KIT, in the treatment of canine MCT. ANIMALS Two hundred and two client-owned dogs with nonmetastatic recurrent or nonresectable grade II or III MCT. METHODS Double-blind, randomized, placebo-controlled phase III clinical trial. Dogs were administered masitinib (12.5 mg… Expand
Safety of masitinib mesylate in healthy cats.
Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Pharmacokinetics of masitinib in cats
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
  • C. London, A. Hannah, +10 authors J. Cherrington
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
Treatment of canine mast cell tumors with CCNU (lomustine).
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
  • S. Eckhardt, J. Rizzo, +15 authors E. Rowinsky
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
  • N. Pryer, Leslie B. Lee, +4 authors C. London
  • Medicine, Biology
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
Mast cell tumors in the dog.
  • C. London, B. Séguin
  • Medicine
  • The Veterinary clinics of North America. Small animal practice
  • 2003
...
1
2
3
...